Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 7/9/01 → 10/31/03 |
A Phase III, Multi-National, Multi-Site, Open Label, 32 Week Long Term Follow-Up Study to Assess the Safety and Efficacy of the Engineered Human and Anti-TNFa Anitbody, CDP571, in Patients with Crohn's Disease (013 Patients Entering CDP571-014)
- De Villiers, Willem (PI)